Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma
Open Access
- 4 March 2019
- journal article
- research article
- Published by Springer Nature in Cancer Cell International
- Vol. 19 (1) , 49
Abstract
Hepatocyte nuclear factor 4α (HNF4α) is a tissue-specific transcription factor that regulates the expression of numerous genes in hepatocytes and pancreatic β cells. HNF4α has been reported to affect cell proliferation and chemoresistance in several cancers. However, the role of HNF4α in pancreatic adenocarcinoma (PDAC) has not been studied extensively and remains unclear. By utilizing immunohistochemical (IHC) staining, we measured the expression of HNF4α in PDAC tissues. By silencing HNF4α in PDAC cell lines, we assessed the impact of HNF4α on pancreatic cancer cell proliferation and gemcitabine sensitivity. We used CCK8 and colony formation assays to examine the effect of HNF4α on cell proliferation. A flow cytometry assay was used to assess cell apoptosis. The expression of gemcitabine-related genes was detected by quantitative real‑time PCR (qRT-PCR) and Western blotting. IHC was utilized to assess the correlation between HNF4α and human equilibrative nucleoside transporter 1 (hENT1) expression in PDAC patients. Chromatin immunoprecipitation (ChIP) and dual‑luciferase reporter assays were used to confirm that hENT1 is a target gene of HNF4α. Increased HNF4α expression was detected in PDAC tissues; patients with higher HNF4α expression displayed worse prognosis. To elucidate the function of HNF4α, we examined its role in pancreatic cancer cell proliferation, apoptosis and gemcitabine resistance. In HNF4α-silenced Capan-1 and MiaPaCa-2 cells, we observed decreased cell proliferation and increased sensitivity to gemcitabine compared to those of controls. The mechanism of HNF4α in gemcitabine-related chemosensitivity was then explored. In response to HNF4α silencing, the expression levels of gemcitabine-related proteins, hENT1 and deoxycytidine kinase (dCK) were significantly increased. Additionally, hENT1 was negatively correlated with HNF4α in PDAC tissue samples. Moreover, we identified hENT1 as a downstream target of HNF4α. HNF4α is a prognostic marker for overall survival, is required for pancreatic cancer cell proliferation and promotes resistance to gemcitabine by downregulating hENT1. Therefore, targeting HNF4α might reverse gemcitabine resistance and provide novel treatment strategies for PDAC.Keywords
Funding Information
- National Natural Science Foundation of China (81502031, 81602085)
- Distinguished Middle-Aged and Young Scientist Encourage and Reward Foundation of Shandong Province (81625016)
- Shanghai Sailing Program (16YF1401800)
This publication has 61 references indexed in Scilit:
- Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapyTrends in Pharmacological Sciences, 2012
- DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer CellsPLOS ONE, 2012
- Regulation of ENT1 expression and ENT1-dependent nucleoside transport by c-Jun N-terminal kinaseBiochemical and Biophysical Research Communications, 2011
- Expression Profiling of Nuclear Receptors in the NCI60 Cancer Cell Panel Reveals Receptor-Drug and Receptor-Gene InteractionsMolecular Endocrinology, 2010
- Pancreatic CancerNew England Journal of Medicine, 2010
- High glucose, nitric oxide, and adenosine: a vicious circle in chronic hyperglycaemia?Cardiovascular Research, 2010
- Sonic Hedgehog Promotes Desmoplasia in Pancreatic CancerClinical Cancer Research, 2008
- p21 and p27: roles in carcinogenesis and drug resistanceExpert Reviews in Molecular Medicine, 2008
- AR, the cell cycle, and prostate cancerNuclear Receptor Signaling, 2008
- Two Functional Modes of a Nuclear Receptor-Recruited Arginine Methyltransferase in Transcriptional ActivationMolecular Cell, 2006